Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Rubicon Genomics New CEO to Focus on SNP Scoring for Personalized Medicine

NEW YORK, June 22 - Rubicon Genomics' new CEO, Thomas Collet, told GenomeWeb Friday that he hopes to target his startup's SNP scoring technology towards applications in personalized medicine.

Collet joined Rubicon, an Ann Arbor, Mich.-based developer of DNA amplification technology, from Tullis-Dickerson, a healthcare venture fund in Ann Arbor where he was general partner. Prior to that, Collet served as vice president for business development at Integrated Protein Technologies, a unit of Monsanto. Collet also worked as a consultant to pharmaceutical and healthcare companies at McKinsey. 

Until Collet joined the company, John Langmore, a co-founder of Rubicon Genomics on leave from the biophysics department of the University of Michigan in Ann Arbor, served as acting CEO. Langmore founded the company in 1998 along with Vladimir Makarov, a scientist formerly with the Engelhardt Institute of Molecular Biology in Moscow.

Rubicon specializes in developing alternatives to PCR for amplifying DNA sequences and identifying SNPs. The company's technology, called OmniPlex, involves reformatting chromosomes into new molecules called plexisomes that are more easily amplified and manipulated, the company said in a statement. The technology may ultimately have applications in personalized medicine, Collet said. 

To reformat the chromosomes, Rubicon uses an enzymatic reaction called Nick Translation that breaks down the DNA into discrete strands of equal length. DNA in this format can be easily searched for multiple SNPs, Collet said, and the technology could allow Rubicon to offer SNP scoring services at less than one cent per SNP.

The company has demonstrated that the technique works in E. coli , and is currently working with an unnamed collaborator to sequence microbial genomes using the technology, Collet said. Within three years, Rubicon hopes to have developed applications for the technology in personalized medicine, such as searching a patient's genome for up to 100,000 different SNPs simultaneously.

The company also said Friday that the US Patent and Trademark Office had issued a patent on the company's OmniPlex technology. 

Rubicon received $1.75 million in venture funding in May of 2000, and just received an additional $1.9 million from the Michigan Life Sciences Corridor, a state initiative to redistribute settlements from tobacco lawsuits to life science businesses, Collet said. The company hopes to see revenue from research services collaborations by the end of the year, and from personalized medicine services sometime in 2002.  
The Scan

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.